| DOI | Trouver le DOI : https://doi.org/10.1021/jz201664h |
|---|
| Auteur | Rechercher : Das, Gautom Kumar; Rechercher : Johnson, Noah J. J.; Rechercher : Cramen, Jordan; Rechercher : Blasiak, Barbara1; Rechercher : Latta, Peter1; Rechercher : Tomanek, Boguslaw1; Rechercher : van Veggel, Frank C. J. M. |
|---|
| Affiliation | - Conseil national de recherches du Canada. Institut du biodiagnostic du CNRC
|
|---|
| Format | Texte, Article |
|---|
| Résumé | A major limitation of the commonly used clinical MRI contrast agents (CAs) suitable at lower magnetic field strengths (<3.0 T) is their inefficiency at higher fields (>7 T), where next-generation MRI scanners are going. We present dysprosium nanoparticles (β-NaDyF4 NPs) as T2 CAs suitable at ultrahigh fields (9.4 T). These NPs effectively enhance T2 contrast at 9.4 T, which is 10-fold higher than the clinically used T2 CA (Resovist). Evaluation of the relaxivities at 3 and 9.4 T show that the T2 contrast enhances with an increase in NP size and field strength. Specifically, the transverse relaxivity (r2) values at 9.4 T were 64 times higher per NP (20.3 nm) and 6 times higher per Dy3+ ion compared to that at 3 T, which is attributed to the Curie spin relaxation mechanism. These results and confirming phantom MR images demonstrate their effectiveness as T2 CAs in ultrahigh field MRIs. |
|---|
| Date de publication | 2012-02-03 |
|---|
| Dans | |
|---|
| Langue | anglais |
|---|
| Publications évaluées par des pairs | Oui |
|---|
| Numéro NPARC | 21268894 |
|---|
| Exporter la notice | Exporter en format RIS |
|---|
| Signaler une correction | Signaler une correction (s'ouvre dans un nouvel onglet) |
|---|
| Identificateur de l’enregistrement | a08cbca3-f8a0-4521-a3ff-7971d8034220 |
|---|
| Enregistrement créé | 2013-11-22 |
|---|
| Enregistrement modifié | 2020-04-21 |
|---|
